Traws Pharma
TRAW
27 hedge funds and large institutions have $1.27M invested in Traws Pharma in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
17% more funds holding
Funds holding: 23 → 27 (+4)
0.01% less ownership
Funds ownership: 0.35% → 0.34% (-0.01%)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
42% less capital invested
Capital invested by funds: $2.19M → $1.27M (-$919K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$28K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$21.3K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$9.97K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$205 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$137 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$46.5K |
| 2 |
Two Sigma Advisers
New York
|
-$44.3K |
| 3 |
Two Sigma Investments
New York
|
-$30.2K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$5.09K |
| 5 |
Millennium Management
New York
|
-$981 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Qube Research & Technologies (QRT)
London,
United Kingdom
| $2 | – | – | – |
|
|
S
27
SignatureFD
Atlanta,
Georgia
| – | -$472 | -16 | Closed |
|
28
Fidelity Investments
Boston,
Massachusetts
| – | -$4 | – | – |
|
29
Simplex Trading
Chicago,
Illinois
| – | +$91 | +4 | New |
|
|
30
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$137 | +6 | +300% |
|
TRAW Hedge Fund Activity: Q3 2023 in Review
27 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q3 2023, worth a combined $1.27M — down 42% from $2.19M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new TRAW positions and 1 closed out — a net gain of 4 holders — while 3 added to existing stakes and 5 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $28K. The largest seller was Renaissance Technologies, cutting an estimated $46.5K.
- 27 institutional investors held Traws Pharma (TRAW) as of Q3 2023, up from 23 in Q2 2023.
- Funds reported $1.27M of Traws Pharma stock for Q3 2023, down 42% quarter-over-quarter.
- 5 funds opened new Traws Pharma positions in Q3 2023 and 1 closed out, a net change of +4 holders.
- The largest Traws Pharma buyer in Q3 2023 was Susquehanna International Group, an estimated $28K added.
- The largest Traws Pharma seller in Q3 2023 was Renaissance Technologies, an estimated $46.5K sold.
Based on aggregated 13F filings for Q3 2023.